HIV Type 1 Subtype A Envelope Genetic Evolution in a Slow Progressing Individual with Consistent Broadly Neutralizing Antibodies

2009 ◽  
Vol 25 (11) ◽  
pp. 1165-1169 ◽  
Author(s):  
Tessa Dieltjens ◽  
Nathalie Loots ◽  
Katleen Vereecken ◽  
Katrijn Grupping ◽  
Leo Heyndrickx ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Genetic Evolution ◽  
Broadly Neutralizing Antibodies ◽  
Hiv Type 1 ◽  
Subtype A

scholarly journals Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising

2015 ◽  
Vol 112 (37) ◽  
pp. 11654-11659 ◽  
Author(s):  
Shishi Luo ◽  
Alan S. Perelson
Keyword(s):  
Computational Model ◽  
Neutralizing Antibodies ◽  
Competitive Exclusion ◽  
Adaptive Immune System ◽  
Broadly Neutralizing Antibodies ◽  
Single Strain ◽  
Hiv Type 1 ◽  
Autologous Antibodies ◽  
Hiv 1

The past decade has seen the discovery of numerous broad and potent monoclonal antibodies against HIV type 1 (HIV-1). Eliciting these antibodies via vaccination appears to be remarkably difficult, not least because they arise late in infection and are highly mutated relative to germline antibody sequences. Here, using a computational model, we show that broad antibodies could in fact emerge earlier and be less mutated, but that they may be prevented from doing so as a result of competitive exclusion by the autologous antibody response. We further find that this competitive exclusion is weaker in infections founded by multiple distinct strains, with broadly neutralizing antibodies emerging earlier than in infections founded by a single strain. Our computational model simulates coevolving multitype virus and antibody populations. Broadly neutralizing antibodies may therefore be easier for the adaptive immune system to generate than previously thought. If less mutated broad antibodies exist, it may be possible to elicit them with a vaccine containing a mixture of diverse virus strains.

Characteristics of the env Genes of HIV Type 1 Quasispecies in Long-Term Nonprogressors With Broadly Neutralizing Antibodies

2008 ◽  
Vol 47 (3) ◽  
pp. 274-284 ◽  
Author(s):  
Martine Braibant ◽  
Henri Agut ◽  
Christine Rouzioux ◽  
Dominique Costagliola ◽  
Brigitte Autran ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Broadly Neutralizing Antibodies ◽  
Hiv Type 1

Genetic Analysis of Human Immunodeficiency Virus in Abidjan, Ivory Coast Reveals Predominance of HIV Type 1 Subtype A and Introduction of Subtype G

1999 ◽  
Vol 15 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Dennis L. Ellenberger ◽  
Danuta Pieniazek ◽  
John Nkengasong ◽  
Chi-Cheng Luo ◽  
Sushil Devare ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Genetic Analysis ◽  
Ivory Coast ◽  
Immunodeficiency Virus ◽  
Hiv Type 1 ◽  
Subtype A

HIV Type 1 Subtype E-Infected Patients with Broadened, Dual (B/E) V3 Loop Serology Have Increased Cross-Neutralizing Antibodies

2001 ◽  
Vol 17 (1) ◽  
pp. 69-79 ◽  
Author(s):  
Victoria R. Polonis ◽  
Mark S. de Souza ◽  
Penprapa Chanbancherd ◽  
Somsak Chantakulkij ◽  
Achara Jugsudee ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
V3 Loop ◽  
Hiv Type 1

scholarly journals Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies

Vaccines ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 76 ◽  
Author(s):  
Mitch Brinkkemper ◽  
Kwinten Sliepen
Keyword(s):  
Envelope Glycoprotein ◽  
Neutralizing Antibodies ◽  
Critical Role ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Broadly Neutralizing Antibodies ◽  
Viral Membrane ◽  
Immunodeficiency Virus ◽  
Hiv 1

The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env.

scholarly journals Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

2014 ◽  
Vol 211 (12) ◽  
pp. 2361-2372 ◽  
Author(s):  
Florian Klein ◽  
Lilian Nogueira ◽  
Yoshiaki Nishimura ◽  
Ganesh Phad ◽  
Anthony P. West ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Neutralizing Antibodies ◽  
Viral Escape ◽  
Humanized Mice ◽  
Broadly Neutralizing Antibodies ◽  
Virus Escape ◽  
Immunodeficiency Virus ◽  
Shiv Infection ◽  
Hiv 1

Antibody-mediated immunotherapy is effective in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope. In contrast, single bNAbs can control simian–human immunodeficiency virus (SHIV) infection in immune-competent macaques, suggesting that the host immune response might also contribute to the control of viremia. Here, we investigate how the autologous antibody response in intact hosts can contribute to the success of immunotherapy. We find that frequently arising antibodies that normally fail to control HIV-1 infection can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants.

scholarly journals Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope

2019 ◽  
Vol 2019 ◽  
pp. 1-13 ◽  
Author(s):  
Karim Dorgham ◽  
Nicolas Pietrancosta ◽  
Amel Affoune ◽  
Olivier Lucar ◽  
Tahar Bouceba ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Molecular Design ◽  
Docking Studies ◽  
Viral Envelope ◽  
Broadly Neutralizing Antibodies ◽  
Immunodeficiency Virus ◽  
Surface Envelope ◽  
Hiv 1

The design of immunogens susceptible to elicit potent and broadly neutralizing antibodies against the human immunodeficiency virus type 1 (HIV-1) remains a veritable challenge in the course of vaccine development. Viral envelope proteins adopt different conformational states during the entry process, allowing the presentation of transient neutralizing epitopes. We focused on the highly conserved 3S motif of gp41, which is exposed to the surface envelope in its trimeric prefusion state. Vaccination with a W614A-modified 3S peptide induces in animals neutralizing anti-HIV-1 antibodies among which we selected clone F8. We used F8 as bait to select for W614A-3S phage-peptide mimics. Binding and molecular docking studies revealed that F8 interacts similarly with W614A-3S and a Mim_F8-1 mimotope, despite their lack of sequence homology, suggesting structural mimicry. Finally, vaccination of mice with the purified Mim_F8-1 phage elicited HIV-1-neutralizing antibodies that bound to the cognate W614A-3S motif. Collectively, our findings provide new insights into the molecular design of immunogens to elicit antibodies with neutralizing properties.

Short Communication: In VitroSynergy between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 gp41

2008 ◽  
Vol 24 (12) ◽  
pp. 1537-1544 ◽  
Author(s):  
Renee Hrin ◽  
Donna L. Montgomery ◽  
Fubao Wang ◽  
Jon H. Condra ◽  
Zhiqiang An ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Short Communication ◽  
Hiv Type 1 ◽  
Heptad Repeats
Sign in / Sign up

Export Citation Format

Share Document